Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Income from Continuing Operations (2016 - 2025)

Arcadia Biosciences' Income from Continuing Operations history spans 12 years, with the latest figure at 1375000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 65.94% year-over-year to 1375000.0; the TTM value through Dec 2025 reached 2498000.0, up 49.61%, while the annual FY2025 figure was 2339000.0, 45.82% up from the prior year.
  • Income from Continuing Operations reached 1375000.0 in Q4 2025 per RKDA's latest filing, down from 1152000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3155000.0 in Q2 2023 to a low of 9554000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 2133250.0, with a median of 1639000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 183.09% in 2023, then tumbled 793.14% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 9554000.0 in 2021, then skyrocketed by 66.72% to 3180000.0 in 2022, then skyrocketed by 85.79% to 452000.0 in 2023, then crashed by 793.14% to 4037000.0 in 2024, then surged by 65.94% to 1375000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Income from Continuing Operations are 1375000.0 (Q4 2025), 1152000.0 (Q3 2025), and 501000.0 (Q2 2025).